JP2023000322A - Antiviral agents, antiviral food compositions, and antiviral cosmetic compositions - Google Patents

Abstract

To provide novel antiviral agents, antiviral food compositions and antiviral cosmetic compositions against coronavirus.SOLUTION: The problems are solved by an antiviral agent used for the prevention or treatment of viral infections and/or pneumonia whose pathogens are viruses belonging to the coronavirus family, an antiviral food composition used for the prevention or improvement of viral infections and/or pneumonia whose pathogens are viruses belonging to the coronavirus family and an antiviral cosmetic composition used for the prevention of viral infections whose pathogens are viruses belonging to the coronavirus family, containing an Euglena extract as an active ingredient. At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.SELECTED DRAWING: Figure 1

Description

The present invention provides novel antiviral agents, antiviral food compositions and antiviral cosmetic compositions, particularly containing Euglena-derived substances as active ingredients, antiviral agents, antiviral food compositions and antiviral It relates to a cosmetic composition.

Viral infectious diseases are infectious diseases caused by viruses, which are pathogens present in the environment (air, water, soil, animals, etc.) and enter the human body, and end with local epidemics. However, movement of animals (especially humans) can spread infection on a global scale and become a public health problem.

In particular, infectious diseases caused by coronavirus, which is the cause of the novel coronavirus infectious disease (COVID-19), have become a serious social problem. Viral infections can be transmitted through "droplets," which are tiny particles that fly out of your mouth or nose when you cough or sneeze.

On the other hand, Euglena (genus name: Euglena, Japanese name: Euglena) is attracting attention as a biological resource that is expected to be used as food, feed, fuel, and the like. Euglena contains 59 types of nutrients, including vitamins, minerals, amino acids, and unsaturated fatty acids, which correspond to most of the nutrients necessary for human life. It has been proposed for its use and possible use as a food source in poor areas where necessary nutrients cannot be obtained.

Patent Document 1 describes an antiviral agent containing a Euglena-derived substance as an active ingredient and used for the prevention or treatment of influenza virus infection. Specifically, mice given orally with euglena, paramylon, or amorphous paramylon had a significantly higher survival rate after influenza virus infection and decreased virus titers compared to control mice. there is

In addition, Patent Document 2 describes that Euglena-derived substances such as Euglena, hot water extracts of Euglena, paramylon or amorphous paramylon have an anti-rotavirus effect. Furthermore, Patent Document 3 describes that Euglena has an anti-norovirus effect.

Japanese Patent No. 6307153 Japanese Patent No. 6114484 Japanese Patent No. 6139813

As shown in Patent Documents 1 to 3, the type of Euglena-derived substance that exerts an antiviral effect differs depending on the type of virus, and Euglena-derived substances that exert an antiviral effect against viruses belonging to the Coronaviridae family have been investigated. was not

The present invention has been made in view of the above problems, and an object of the present invention is to provide novel antiviral agents, antiviral food compositions, and antiviral cosmetic compositions against viruses belonging to the Coronaviridae family. to provide.

As a result of intensive research, the present inventors found that the Euglena extract has the effect of inhibiting the growth of viruses belonging to the Coronaviridae family.

Therefore, the above-mentioned problems are solved by the antiviral agent of the present invention, which contains an euglena extract as an active ingredient and is used for the prevention or treatment of viral infections whose pathogens are viruses belonging to the Coronaviridae family. be done.
At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

In addition, the above-mentioned object is solved by the antiviral agent of the present invention, which contains an Euglena extract as an active ingredient and is used for the prevention or treatment of pneumonia caused by a virus belonging to the Coronaviridae family as a pathogen. .
At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

Moreover, the above-mentioned object is that the antiviral food composition of the present invention contains an Euglena extract as an active ingredient and is used for the prevention or amelioration of viral infections whose pathogens are viruses belonging to the Coronaviridae family. , is resolved by
At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

In addition, according to the antiviral food composition of the present invention, the Euglena extract is contained as an active ingredient, and is used for the prevention or improvement of pneumonia caused by a virus belonging to the Coronaviridae family as a pathogen. resolved.
At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

In addition, the above-mentioned object is that the antiviral cosmetic composition of the present invention contains an Euglena extract as an active ingredient and is used to prevent viral infections whose pathogens are viruses belonging to the Coronaviridae family. resolved by
At this time, the Euglena extract is preferably a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide novel antiviral agents, antiviral food compositions, and antiviral cosmetic compositions against viruses belonging to the Coronaviridae family.

Fig. 10 is a graph showing the results of coronavirus multiplication infection rate by Euglena extract.

An embodiment of the present invention will be described below with reference to FIG. The present embodiment relates to an antiviral agent, an antiviral food composition, and an antiviral cosmetic composition that contain an Euglena extract as an active ingredient and are used against viruses belonging to the Coronaviridae family.

<Coronavirus>
Viruses targeted in the present embodiment are viruses belonging to the Coronaviridae family. The Coronaviridae is a family of enveloped, single-stranded, positive-strand RNA viruses in the viral taxonomy.

Examples of coronaviruses include SARS virus, which is the causative agent of severe acute respiratory syndrome (SARS), which was prevalent in 2003, and MERS virus, which is the causative agent of Middle East respiratory syndrome (MERS). , 2019 novel coronavirus (2019-nCoV, SARS-CoV-2), which is a coronavirus belonging to the SARS-related coronavirus (SARSr-CoV) that causes the new coronavirus infection (COVID-19), and mutations of these viruses Although the body is exemplified, it is not particularly limited.

<Euglena>
In the present embodiment, the term "euglena" includes taxonomically classified microorganisms classified into the genus Euglena, variants thereof, variants thereof, and closely related species of the family Euglenaceae. Here, the genus Euglena is a group of eukaryotic organisms belonging to Excoverta, Euglenozoa, Euglenomycetes, Euglenoides, and Euglenaceae.

Species included in the genus Euglena specifically include Euglena chadefaudii, Euglena deses, Euglena gracilis, Euglena granulata, Euglena mutabilis, Euglena proxima, Euglena spirogyra, and Euglena viridis. As Euglena, E. gracilis, particularly E. gracilis Z strain can be used, but in addition, Euglena gracilis Z strain mutant strain SM-ZK strain (chloroplast-deficient strain), variants of E. gracilis var. bacillaris, gene mutant strains such as chloroplast mutant strains of these species, and other Euglenoids such as Astasia longa.

Euglenoids are widely distributed in freshwater such as ponds and marshes, and may be used by separating from them, or any already isolated Euglenoids may be used. The genus Euglena includes all its variants. These mutant strains also include those obtained by genetic methods such as recombination, transduction, and transformation.

(Euglenoid algae)
In the present embodiment, Euglenoid algae can be used as Euglena. Euglenoid cells separated by centrifugation, filtration, sedimentation, or the like can be used as they are as Euglenoid alga bodies. Euglena living cells can be used as they are after being harvested from the culture vessel, but they are preferably washed with water or physiological saline. Alternatively, the Euglenoid alga body may be used in the form of a dispersion in a liquid such as water. In the present embodiment, it is preferable to use dry Euglena alga bodies (Euglena powder) obtained by freeze-drying or spray-drying living Euglena cells as Euglena alga bodies.

Furthermore, a mechanically processed product of alga bodies obtained by subjecting living Euglena cells to ultrasonic irradiation treatment or mechanical treatment such as homogenization may be used as the Euglena alga bodies. Alternatively, a dried mechanically processed product obtained by subjecting a mechanically processed product to a drying treatment may be used as the Euglenoid algal body.

(Euglena extract)
In this embodiment, an euglena extract (euglena extract) is used as an active ingredient. In the present embodiment, "Euglena aqueous solvent extract" means an extract extracted from Euglena using an aqueous solvent. It is preferable to use a water extract, a hot water extract, an alcohol extract, or a glycol extract of Euglena extracted for several seconds to several tens of hours at ℃. The water used for extraction does not necessarily have to be distilled, pure, or ultrapure water, and may, for example, be tap water or contain impurities, but may contain components that interfere with the extraction of the active ingredient. no water is preferred.

In the present embodiment, "water extract" means an extract with water at 0 to 50°C (excluding 0°C). Here, "water" means water at 0 to 50°C (excluding 0°C). The temperature of the water is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient. Especially preferred is 10 to 30°C.

In this embodiment, "hot water extract" means an extract with water at a temperature higher than 50°C, and can also be called a "hot water extract". Here, “hot water” means water having a temperature higher than 50° C., and is a concept that includes “hot water”, including water in a boiling state. Moreover, it is not limited to hot water in a liquid state, but also includes hot water in a gaseous state and a supercritical state. The temperature of the hot water is not particularly limited as long as the active ingredient can be extracted sufficiently without affecting the active ingredient. °C and 100°C or less.

The pH of the water used for extraction is not particularly limited as long as the active ingredient can be sufficiently extracted without affecting the active ingredient, preferably pH 4 to 10, more preferably pH 5 to 9. , particularly preferably pH 6-8.

In the present embodiment, as the aqueous solvent, one or more solvents that can sufficiently extract the active ingredient without affecting the active ingredient and that can be used for extraction are usually selected. may be used. Examples include, but are not limited to, water, alcohols, glycols, and the like. Alcohols include ethanol, methanol, n-propanol, isopropanol and the like. Glycols include 1,3-butylene glycol (BG) and propylene glycol. Other aqueous solvents include acetone and the like. These solvents may be used alone or as an aqueous solution, or may be used as a mixed solvent of any two or three or more.

The temperature of the aqueous solvent used for extraction is, for example, 0° C. or higher, and is not particularly limited as long as it does not affect the active ingredients. Aqueous solvents in a boiling or supercritical state can also be used, but it is preferred to use aqueous solvents at 5°C to 600°C, more preferably 10°C to 200°C. Therefore, the aqueous solvent for extraction includes an aqueous solvent in a boiling state or a supercritical state. The amount of the aqueous solvent used for extraction is preferably an amount that can sufficiently dissolve the water-soluble active ingredient contained in Euglena.

The extraction method is also not particularly limited, and for example, extraction can be performed by the method shown below, but the extraction method is not limited to this, and can be freely selected and used. For example, a dry powder of Euglena algae is immersed in an aqueous solvent for a predetermined time and then centrifuged or filtered, or a dry powder of Euglena algae is added to an aqueous solvent and shaken to uniformly disperse, followed by centrifugation or filtration. method, etc. Moreover, in order to promote extraction, it is also possible to heat the aqueous solvent after adding Euglena.

Euglena can be extracted with water by a conventional method as shown below, but not limited thereto. For example, the Euglena tissue and water are placed in a container and allowed to stand for a predetermined period of time with appropriate stirring or shaking, and the obtained extract can be used as a water extract as it is. Moreover, for example, the supernatant obtained by centrifuging such an extract can also be used as an aqueous extract. Also, such an extract or supernatant can be concentrated and dried to remove water and used as an aqueous extract. The water extraction may be carried out by adding a small amount of alcohol, preferably ethanol, to water in an amount of, for example, 10% by mass or less, in order to increase the extraction efficiency and shorten the extraction time. The extraction time for water extraction is not particularly limited as long as the active ingredient is extracted, and can be appropriately set in the range of several seconds to several tens of hours depending on the extraction temperature.

Extraction with hot water can be performed by a commonly used method as shown below, but is not limited thereto. After Euglena is introduced into a commonly used extractor together with water, it is extracted by heating. When boiling water or water in a supercritical state is used for extraction, it is necessary to use an extractor that can withstand the vapor pressure of water. The pressure during extraction can be set to 1 to 5000 atmospheres, preferably 60 to 400 atmospheres.

When performing extraction under high temperature and high pressure, if the extraction time is too long, the active ingredients may decompose or chemical reactions may occur. Therefore, when the extraction is performed under high temperature and high pressure, the extraction time is short, for example, preferably within 3 minutes, more preferably within 1 minute, and particularly preferably within 30 seconds.

The extracted Euglena extract can be used as it is as an active ingredient of the antiviral agent according to the present embodiment. , reverse-phase or normal-phase high-performance liquid chromatography, etc.) to fractionate and use a highly active fraction. Alternatively, the Euglena extract or a fraction thereof can be concentrated and dried to remove the aqueous solvent, and this can be used as an aqueous solvent extract.

(Hydrolyzed euglena extract)
As the Euglena extract, a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena, specifically, a hydrolyzed Euglena extract obtained by enzymatically hydrolyzing and extracting Euglena powder (Euglena algae body) is used. is particularly preferred. Hydrolyzed Euglena extract can be prepared according to the method described in JP-A-2010-90065.

A method for preparing the hydrolyzed Euglena extract will be described below. Purified water is preferably added in an amount (weight) 100 times the amount (weight) of the dried Euglena, and pressure and heat treatment is performed. After that, a proteolytic enzyme is added to treat the algal body. After completion of the treatment, it is deactivated, for example, at 90° C., and the residue and water-soluble components are separated by centrifugation or filtration.

Specifically, the pressure and heat treatment conditions are preferably 100 to 150 ° C. using an autoclave, atmospheric pressure to 0.255 MPa, and heat and pressure treatment for 1 minute to 30 minutes. It is preferable to heat and pressurize at 0.14 MPa and 121° C. for 10 minutes. As the proteolytic enzyme, for example, pepsin, pancreatin, papain, and other commonly used enzymes having protease activity may be used alone or in combination. It is preferable to employ an endo-type peptidase to decompose into .

Pantidase MP and Alloase AP-10 manufactured by Yakult Pharmaceutical Co., Ltd. can also be used as commercially available proteases. The concentration of the enzyme added, the pH and reaction temperature of the reaction solution, and other conditions may be selected optimally for each enzymatic agent.

The water-soluble component thus obtained can be used as it is, but it can also be used after being subjected to purification operations such as fractionation, deodorization, decolorization, concentration, etc., as long as the effects of the present invention are not lost.

<Antiviral agent>
The antiviral agent of the present embodiment can be used as a therapeutic agent for coronavirus infection by being administered to a patient with a virus infection whose pathogen is a virus belonging to the coronavirus family or to a non-human animal suffering from coronavirus infection. , and can be used as therapeutic agents for coronavirus disease. In addition, it is used as a prophylactic agent for coronavirus infections in humans before contracting coronavirus infections, humans at risk of coronavirus infections, and animals other than these, and as a prophylactic agent for coronavirus-related diseases. can also The antiviral agent of the present embodiment can also be used as a prophylactic or therapeutic agent for pneumonia caused by a virus belonging to the coronavirus family.

<Application>
The antiviral agent according to the present embodiment is configured as a pharmaceutical composition, a food composition such as a health food, or a cosmetic composition, and is used or ingested prophylactically to inhibit the growth of viruses belonging to the coronavirus family. • Administered. Euglena-derived substances such as Euglena extracts can be ingested as food and have no side effects, so they can be used, ingested, and administered continuously.

(Pharmaceutical composition)
In the field of medicine, the antiviral agent of the present embodiment is formulated by blending a pharmaceutically acceptable carrier and additives with an amount of Euglena extract that can effectively exhibit the effect of inhibiting the growth of viruses belonging to the Coronaviridae family. provide a pharmaceutical composition having this effect. The pharmaceutical composition may be a drug or a quasi-drug.

The pharmaceutical composition may be applied internally or topically. Therefore, the pharmaceutical composition is used in the form of an oral preparation, an injection such as an intravenous injection, a subcutaneous injection, an intradermal injection, an intramuscular injection and/or an intraperitoneal injection, a transmucosal application, a transdermal application, and the like. be able to. The dosage form of the pharmaceutical composition can be appropriately set depending on the application form. Semi-solid formulations such as ointments or gels are included.

The pharmaceutical composition according to this embodiment can contain one or more pharmaceutically acceptable additives by freely selecting them. For example, when the pharmaceutical composition according to this embodiment is applied to an oral formulation, for example, excipients, binders, disintegrants, surfactants, preservatives, coloring agents, flavoring agents, fragrances, stabilizers, preservatives All additives that can be commonly used in the field of pharmaceutical formulations, such as agents, antioxidants, etc., can be contained. In addition, a drug delivery system (DDS) can be used to prepare a sustained-release preparation or the like.

(Food composition)
In the field of foods, the antiviral agent of the present embodiment is obtained by adding an effective amount of Euglena extract as a food material that can effectively exhibit the effect of inhibiting the growth of viruses belonging to the Coronaviridae family into various foods. A food composition having action can be provided. That is, the present invention can provide food compositions labeled as antiviral or the like in the food field. Examples of the food composition include general foods, foods for specified health uses, foods with nutrient function claims, foods with function claims, foods for hospital patients, supplements, and the like. It can also be used as a food additive.

Examples of the food composition include seasonings, processed meat products, processed agricultural products, beverages (lactic acid beverages, soft drinks, alcoholic beverages, carbonated beverages, milk beverages, fruit juice beverages, tea, coffee, nutritional drinks, etc.), powders Beverages (powdered juice, powdered soup, etc.), concentrated drinks, confectionery (candies, cookies, biscuits, gums, gummies, chewables, tablets, chocolate, etc.), breads, cereals and the like. In the case of food for specified health uses, food with nutrient function claims, food with function claims, etc., the shape may be capsule, troche, syrup, granule, powder, or the like.

Foods for Specified Health Uses are foods that contain functional health ingredients that affect physiological functions, etc., and can be labeled as suitable for specific health uses with the permission of the Director-General of the Consumer Affairs Agency. be. In the present invention, it is a food that is marketed with a label indicating a specific health use related to antiviral activity.

A food with nutrient function claims is a food that is used to supplement nutritional ingredients (vitamins and minerals), and the functions of the nutritional ingredients are indicated. In order to be sold as a food with nutrient function claims, the amount of nutrients contained in the recommended daily intake must be within the specified upper and lower limits. also need to

Foods with function claims are foods labeled with functionalities based on scientific evidence under the responsibility of the business operator. Information on the grounds for safety and functionality was submitted to the Commissioner of the Consumer Affairs Agency before sales.

In the food composition according to the present embodiment, in addition to the Euglena extract, it is possible to freely select and blend one or more components that can be used in ordinary food compositions. For example, all additives that can be commonly used in the food field, such as various seasonings, preservatives, emulsifiers, stabilizers, fragrances, coloring agents, preservatives, and pH adjusters, can be included.

(Cosmetic composition)
The Euglena extract, which is the active ingredient of the antiviral agent according to this embodiment, can also be blended in a cosmetic composition. In other words, the antiviral agent according to the present embodiment can be suitably used in cosmetic compositions by utilizing the antiviral action of the Euglena extract. The cosmetic composition can be applied to any form of cosmetics. For example, skin care cosmetics such as cleansing agents, facial cleansers, lotions, lotions, milky lotions, creams, serums, packs, and scrubs, and makeup such as foundations, concealers, makeup bases, lipsticks, blushers, eyeshadows, and eyeliners. It can be applied to cosmetics, sunscreen cosmetics, and the like.

In the cosmetic composition according to the present embodiment, in addition to the Euglena extract, which is the active ingredient of the antiviral agent according to the present embodiment, one or more components that can be used in ordinary cosmetic compositions are added. It is possible to freely select and blend them. For example, base materials, preservatives, emulsifiers, coloring agents, preservatives, surfactants, ultraviolet absorbers, antioxidants, moisturizing agents, ultraviolet absorbers, fragrances, antiseptic antifungal agents, extender pigments, coloring pigments, alcohols, All additives that can normally be used in the cosmetic field, such as water, can be included.

In the cosmetic composition according to this embodiment, the content of the antiviral agent is not particularly limited, and can be freely set according to the purpose.

EXAMPLES The present invention will be specifically described below based on specific examples, but the present invention is not limited to these.

<Example 1: Euglena hot water extract>
As the Euglena extract of Example 1, a Euglena hot water extract was used. Euglena hot water extract was prepared by the following procedure. Euglena gracilis powder (Euglenoid algae, manufactured by Euglena Co., Ltd.) was extracted with hot water at 95° C. under normal pressure, and then filtered under reduced pressure to separate the residue to obtain a hot water extract. A sample obtained by sterilizing the obtained hot water extract with a 0.45 μm filter was used as 100% Euglena hot water extract undiluted solution.

<Example 2: Hydrolyzed Euglena extract>
As the Euglena extract of Example 2, a hydrolyzed Euglena extract, which is a water-soluble component extracted by proteolytic decomposition of Euglena gracilis cells, was used. The hydrolyzed Euglena extract is obtained by adding 100 times the amount of purified water to 1 g of Euglena gracilis powder (Euglena algae, manufactured by Euglena Co., Ltd.), heating to a pressure of 0.1 MPa and a temperature of 12 ° C., and heating for 10 minutes. pressure treated. After that, 5% of the total amount of proteolytic enzyme of endo-type protease (for example, pantidase MP manufactured by Yakult Pharmaceutical Co., Ltd.) was added, and the mixture was reacted with stirring at 35° C. for 16 hours. After the reaction, the water-soluble component was fractionated by filtering using a filter paper. A sample obtained by sterilizing the water-soluble component with a 0.45 μm filter was used as 100% hydrolyzed Euglena extract undiluted solution.

<Test Example 1 Coronavirus infection inhibition test>
Using the antiviral agents of Examples 1 and 2, a test was conducted to confirm the effect of inhibiting the growth of coronavirus. Specifically, the following method was used.

(Method)
K-ML2 (AT) clone 35 cells are used as host cells, and ARS-CoV-2/Hu/DP/Kng/19-020 (GenBank accession number: LC528232.1) strain is used as virus, and liquid MEM alpha (Gibco) medium containing 10% FBS (Fetal Bovine Serum) was used as the medium. First, K-ML2(AT) clone 35 cells were seeded in a 96-well plate at 2.0×10 ⁴ cells/well.

Next, K-ML2 (AT) clone 35 cells ARS-CoV-2 / Hu / DP / Kng / 19-020 (GenBank accession number: LC528232.1) virus with a final concentration of 1.0 × 10 ⁴ copies / uL was added so that

Thereafter, the Euglena extracts of Examples 1 and 2 were added to the liquid medium so as to contain a predetermined concentration, and cultured in a CO ₂ incubator for 72 hours.
After that, the supernatant containing the virus released from the infected cells was collected, the virus-derived gene was detected by PCR, and the virus growth inhibition rate (%) was calculated therefrom.

(result)
Analyzing the above test results, Euglena extract (Example 1) at each concentration (2.5%, 5%, 10%, 20%) and Euglena extract (Example 2) 1% virus proliferation infection rate A comparative graph is shown in FIG.

The virus growth inhibition rate at each concentration (2.5%, 5%, 10% and 20%) in Example 1 was 10.8%, 51.2%, 80.5% and 95%, respectively. The virus growth inhibition rate increased with increasing concentration of Euglena.
In addition, the virus growth inhibition rate of Example 2 was 98.8%. The viral growth inhibition rate of remdesivir in positive subjects was 98.8%.

Claims (10)

containing Euglena extract as an active ingredient,
An antiviral agent characterized by being used for the prevention or treatment of a viral infection whose pathogen is a virus belonging to the Coronaviridae family. 2. The antiviral agent according to claim 1, wherein the Euglena extract is a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena. containing Euglena extract as an active ingredient,
An antiviral agent characterized by being used for the prevention or treatment of pneumonia caused by a virus belonging to the Coronaviridae family as a pathogen. 4. The antiviral agent according to claim 3, wherein the Euglena extract is a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena. containing Euglena extract as an active ingredient,
An antiviral food composition characterized by being used for the prevention or amelioration of a viral infection whose pathogen is a virus belonging to the Coronaviridae family. 6. The antiviral food composition according to claim 5, wherein the Euglena extract is a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena. containing Euglena extract as an active ingredient,
An antiviral food composition characterized by being used for the prevention or amelioration of pneumonia caused by a virus belonging to the Coronaviridae family as a pathogen. 8. The antiviral food composition according to claim 7, wherein the Euglena extract is a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena. containing Euglena extract as an active ingredient,
An antiviral cosmetic composition characterized by being used for prevention of viral infections whose pathogens are viruses belonging to the Coronaviridae family. 10. The antiviral cosmetic composition according to claim 9, wherein the Euglena extract is a water-soluble component extracted by proteolytic decomposition of algal cells belonging to the genus Euglena.

Images